Biologics CMC Series (3): ICH Q5E Comparability After Manufacturing Changes

Biologics manufacturing processes rarely remain unchanged throughout a product's lifecycle. Early development may begin in a small bioreactor, followed by scale-up for pivotal studies and commercial supply. A company may change culture media, adjust purification steps, introduce new equipment, transfer production to another facility, or move the process to a new CDMO.

Each change may have a sound business or technical rationale: improving yield, increasing purity, reducing cost, expanding capacity, or addressing process robustness. For biologics, however, the manufacturing process does more than produce the product—it also helps define it.

Cell-culture conditions can alter glycosylation. Purification changes may shift aggregate, fragment, and host-cell-protein profiles. Changes to formulation, filling, container closure, or hold times can affect oxidation, deamidation, particles, and long-term stability.

The key question after a change is therefore not simply:

Does the post-change product pass its release specifications?

It is:

Are the pre-change and post-change products highly similar, and could any observed differences adversely affect product quality, safety, or efficacy?

That is the central question of ICH Q5E comparability.

Executive Summary

• Comparability does not require the pre-change and post-change products to be identical. It requires them to be highly similar, with no adverse effect on safety or efficacy.

• Passing specifications before and after a change is not sufficient by itself. Specifications support routine control; comparability typically requires broader and more sensitive side-by-side characterization.

• A comparability exercise should start with a mechanism-based risk assessment of the change, not with a fixed “three lots versus three lots” rule.

• Methods must have sufficient sensitivity and discriminatory power for the expected change; orthogonal methods may be needed.

• Batch selection should consider representativeness, scale, process version, clinical relevance, reference standards, storage history, and sample comparability.

• Stability, in-process data, process validation, impurity clearance, and historical trends are part of the evidence package.

• If analytical evidence cannot adequately reduce residual uncertainty, nonclinical, PK/PD, immunogenicity, or clinical bridging may be needed.

• Scientific comparability and the regulatory reporting category are separate determinations. In the United States, classification follows 21 CFR 601.12 and applicable FDA guidance; in the EU, it follows the current variations framework.

• FDA comparability protocols and ICH Q12 PACMPs can make future changes more predictable, but they do not eliminate change assessment, data generation, or regional filing requirements.

Comparability in Plain Language

Imagine a bakery replacing a small oven with a larger commercial oven. The recipe, ingredients, and target baking time remain the same, but heat transfer, humidity, and airflow cannot be perfectly identical.

It would not be enough to confirm that both loaves are fully baked. The bakery would also compare appearance, weight, internal structure, moisture, taste, aroma, and how the bread changes during storage. If small differences do not affect quality, safety, or the consumer experience, the products may still be considered comparable.

Biologics comparability follows the same logic. It does not demand identical numerical results. It uses a scientific, risk-based comparison to show that the post-change product retains its intended quality and does not introduce a new risk to patients.

Comparable Does Not Mean Identical

The central principle of ICH Q5E is that comparability does not require every quality attribute to be identical. Instead:

1. The pre-change and post-change products should be highly similar.

2. Existing product and process knowledge should support interpretation of any differences.

3. Observed differences should not adversely affect safety or efficacy.

This distinction matters because biologics naturally exhibit molecular heterogeneity. A monoclonal antibody may contain multiple glycoforms, charge variants, C-terminal lysine variants, and low levels of size variants. Even without a process change, no two batches are numerically identical in every measurement.

The goal is to distinguish normal batch-to-batch variability, analytical variability, change-related differences without clinical significance, and differences that could affect safety or efficacy. The most difficult judgment is often separating the final two categories.

Comparability does not require every numerical result to be identical. It requires evidence that the products are highly similar and that observed differences do not adversely affect safety or efficacy.

When Does ICH Q5E Comparability Apply?

ICH Q5E was finalized in 2004 and primarily addresses manufacturing-process changes made during development or after approval by the same manufacturer, including a contracted manufacturer, when pre-change and post-change materials can be directly compared.

Its core scope includes proteins, polypeptides, and derivatives—including conjugates—that can be highly purified and appropriately characterized. Common changes include:

• Cell-culture scale-up or scale-down

• Changes to bioreactor type, mixing, aeration, or feeding strategy

• Culture-medium, raw-material, or supplier changes

• Cell-bank, cell-line, or expression-system changes

• Changes to chromatography resin, columns, membranes, or purification sequence

• Changes to viral clearance or inactivation steps

• Changes to TFF, concentration, buffer exchange, or hold conditions

• Formulation, excipient, or concentration changes

• Drug-substance or drug-product site transfers

• Filling-line, container-closure, or device-constituent changes

• Analytical-method or specification changes

The same strategy cannot be applied at the same depth to every modality. Cell and gene therapies, vaccines, complex conjugates, viral vectors, and highly heterogeneous products may not be characterized as comprehensively as monoclonal antibodies. These programs often require earlier regulatory interaction and a broader, product-specific evidence package.

The Core Comparability Exercise Workflow

A mature comparability exercise is designed before the change is implemented—not after post-change batches have been manufactured.

1. Describe the change and its rationale.

2. Perform a mechanism-based risk assessment.

3. Define the product stages and quality attributes to compare.

4. Select representative pre-change and post-change batches and reference materials.

5. Predefine analytical, process, stability, and statistical strategies.

6. Evaluate observed differences and residual uncertainty.

7. Determine whether additional quality, nonclinical, or clinical evidence is required, and complete the appropriate regulatory reporting.

These steps are interconnected. If an upstream change could alter glycosylation and Fc function, then batch selection, glycan analysis, Fc-receptor binding, cell-based assays, PK relevance, and acceptance criteria should all follow the same risk logic.

A mature comparability exercise begins with change description and risk assessment and ends with residual uncertainty and regulatory reporting.

Step 1: Understand the Change Before Listing Tests

The first question is not whether SEC, CE-SDS, and CEX should be run. It is: through what mechanisms could this change alter the product?

Scaling a cell-culture process from 500 L to 2,000 L may affect mixing time, nutrient gradients, dissolved oxygen, pH control, gas transfer, carbon-dioxide accumulation, shear, cell growth, viability, harvest timing, metabolite profiles, glycosylation, charge variants, HCP composition, and downstream process burden.

By contrast, upgrading a non-product-contact monitoring system may present much lower comparability risk if the process controls, operating principles, and approved parameters remain unchanged.

The change label does not determine the risk. What matters is where it acts, how it acts, how detectable its effects are, and how the affected quality attributes relate to clinical performance.

Step 2: Build a Risk-Based Comparability Plan

The risk assessment should consider:

• The affected process step and whether the change contacts product or product-contact material

• The potential for new product-related or process-related impurities

• The ability of downstream steps to clear or buffer the change

• Potentially affected CQAs

• Whether current methods can detect the expected differences

• The strength of the relationship between the attribute and safety or efficacy

• The quality range covered by clinical batches

• Available prior product and process knowledge

• Feasible nonclinical or clinical bridges if analytical data cannot resolve uncertainty

ICH Q9(R1) quality-risk-management principles can support the exercise, but a risk score is not a comparability conclusion. The value of an FMEA is its ability to justify study scope, method sensitivity, batch numbers, and the handling of residual uncertainty.

Step 3: Select the Right Samples and Batches

ICH Q5E does not require a universal fixed number of batches. Batch numbers should reflect change risk, process variability, method performance, available samples, and accumulated product knowledge.

The strategy should address whether pre-change batches truly represent the historical process; whether post-change batches use the intended clinical or commercial process, scale, and site; whether normal variability is represented; whether sample age, storage conditions, and freeze-thaw histories are comparable; which product stages should be tested; and whether pivotal clinical lots, marketed lots, or reference standards should serve as anchors.

Old pre-change retain samples and newly manufactured post-change samples can confound process effects with sample-age effects. Retain-sample, aliquoting, reference-standard, and storage plans should therefore be established before the change whenever possible.

Step 4: Analytical Comparability Goes Beyond Release Testing

Specification tests alone are usually insufficient to assess the effect of a manufacturing change. Release tests confirm routine batch quality; characterization methods increase the ability to detect differences; and comparability methods answer whether a particular change altered the product.

A comprehensive analytical package may include primary structure, intact mass, peptide mapping, post-translational modifications, glycan profiles, charge and size variants, aggregates and fragments, higher-order structure, thermal and colloidal stability, antigen and Fc-receptor binding, cell-based potency, HCP, residual DNA, Protein A, other process-related impurities, particles, and container-closure risks.

When an attribute is important and one method could miss a relevant difference, orthogonal methods should be considered. SEC-HPLC, for example, does not fully replace AUC, DLS, MALS, CE-SDS, or particle methods. Likewise, a binding assay does not automatically represent all cellular functions related to the mechanism of action.

Methods Must Be Fit for the Comparability Question

A validated method is not automatically fit for comparability. A release assay may perform reliably within its approved range but lack the sensitivity to distinguish a subtle, meaningful pre-change/post-change difference.

Method suitability should consider specificity, precision, accuracy, sensitivity, quantitation range, resolution of relevant variants, matrix effects, reference-standard suitability, assay drift, and inter-run variability.

If a change could alter the HCP profile, a validated generic HCP ELISA may still provide incomplete coverage. Orthogonal proteomic analysis or reassessment of assay coverage may be needed. ICH Q5E also recognizes that characterization studies do not always require fully validated methods, provided those methods are scientifically sound and generate reliable results.

Step 5: Define the Acceptance Approach

Not every attribute belongs in the same statistical model. Attributes differ in patient risk, method variability, and process-control capability. Common approaches include descriptive comparisons, quality ranges based on appropriate historical distributions, equivalence testing with predefined margins, tiered approaches based on CQA risk, and an integrated totality-of-evidence assessment.

Statistics cannot replace scientific judgment. Small historical sample sizes, batches from different development stages, and assay-version changes can limit even sophisticated models. Conversely, results that remain within approved specifications may still be concerning if they fall outside established manufacturing-control trends.

Building a Complete Comparability Evidence Package

The Role of Specifications

Specifications remain important, but they are not the entire comparability assessment. After a change, the team should confirm that current tests remain relevant, procedures remain suitable for post-change material, acceptance criteria still control quality, new impurities do not require new tests or limits, and tests for eliminated risks can be removed when justified.

Acceptance criteria should not be widened simply because the post-change distribution is broader. Any specification change should be supported under Q6B principles by process knowledge, characterization, batch data, stability, and clinical experience.

Why Stability Is Often Critical

Some differences are not visible at release but emerge during storage. Trace proteases may drive fragmentation; metal ions or container interactions may accelerate oxidation; formulation changes may alter aggregation pathways; and filling stress may increase particles.

A package may include real-time, accelerated, and stress stability; freeze-thaw; agitation or shipping simulation; in-use stability; and side-by-side degradation profiles. Accelerated and stressed studies can increase sensitivity to subtle differences, but any observed divergence must still be interpreted for its relevance to real-time behavior and clinical risk.

Process Data Are Part of the Evidence

Comparability is not limited to final-product testing. Critical process parameters, in-process controls, intermediate quality, step yields, mass balance, impurity clearance, viral clearance and inactivation, hold times, filter and resin lifetime, PPQ data, and continued-process-verification trends may all be relevant.

A difference may be easiest to detect at an intermediate stage but be cleared or buffered downstream. Conversely, a similar final product does not by itself establish adequate impurity clearance, viral safety, or process robustness. Product comparability and process validation are related, but neither replaces the other.

Process Drift and Cumulative Change

ICH Q5E asks manufacturers to consider whether a sequence of changes has caused drift. A small glycan shift followed by scale-up, raw-material, site, and method changes may gradually move the product away from the quality space represented by pivotal clinical batches.

Lifecycle comparability therefore requires links between clinical and commercial lots, reference-standard lifecycle management, historical trend databases, bridging across analytical-method versions, cumulative change-risk assessment, product quality review, and continued process verification.

Comparability evidence starts with analytical data and process knowledge; nonclinical and clinical evidence is added only when residual uncertainty warrants escalation.

When Are Analytical Data Not Enough?

ICH Q5E follows a stepwise logic: maximize quality evidence first, then add nonclinical or clinical studies only when material uncertainty remains. Escalation may be appropriate when a new or increased impurity has uncertain safety; an attribute difference lacks an established safety or efficacy relationship; the product is too complex for adequate characterization; higher-order structure or multiple biological functions cannot be evaluated reliably; potency assays are weakly linked to the mechanism of action; or a change could affect PK, PD, immunogenicity, or tissue distribution.

Additional evidence may include in-vitro functional studies, relevant animal studies, PK/PD bridging, immunogenicity assessment, or clinical safety and efficacy studies. More animal or clinical testing is not the default. If analytical evidence adequately establishes comparability, repeating nonclinical or clinical studies with post-change product is generally unnecessary.

Five Possible Comparability Outcomes

1. The products are highly similar with no expected adverse effect: comparable.

2. They appear highly similar, but method capability is insufficient: more characterization is needed.

3. Differences are observed but existing knowledge and data show no adverse effect: still comparable.

4. Differences are observed and clinical impact cannot be excluded: nonclinical or clinical evidence is needed.

5. Differences are too large for the products to be considered highly similar: not comparable.

These outcomes capture the essence of the assessment: a detected difference does not automatically mean “not comparable,” and failure to detect a difference does not automatically prove comparability. The conclusion depends on whether the methods can detect important changes and whether their patient impact can be predicted.

Development-Stage Versus Post-Approval Comparability

During early development, processes evolve quickly, batches are limited, and specifications are still maturing. Comparability primarily preserves the interpretability of clinical development—for example, by linking a pivotal-study process to earlier safety and activity data.

Evidence expectations generally increase as a program approaches pivotal trials and marketing authorization because clinical experience becomes tied to a defined product profile, the commercial control strategy should converge, major efficacy and safety studies are difficult to repeat, and unresolved differences may undermine dossier integration.

After approval, the scientific conclusion must be paired with the correct reporting category and implementation timing. The package supports change control, regulatory reporting, and commercial-supply decisions.

Comparability assessment addresses scientific risk; FDA and EU filing routes are determined by regional regulations, change classifications, and procedural requirements.

United States FDA: Comparability and Reporting Category Are Different Questions

CMC changes to an approved BLA are principally managed under 21 CFR 601.12. Before distributing product manufactured with a change, the applicant must assess its effect and use appropriate validation, nonclinical, or clinical studies to demonstrate that identity, strength, quality, purity, and potency are not adversely affected.

Common categories include Prior Approval Supplement (PAS), Changes Being Effected in 30 Days (CBE-30), CBE-0 for qualifying changes, and Annual Report for changes with minimal potential for adverse effect.

A strong comparability package does not automatically convert a PAS into an Annual Report. The reporting category must follow the regulation, current FDA guidance, the approved dossier, the nature of the change, and product-specific risk.

What Is an FDA Comparability Protocol?

FDA's 2022 final guidance describes comparability protocols for post-approval CMC changes to NDAs, ANDAs, and BLAs. A protocol is a prospective plan describing the future change, risk assessment, tests, analytical procedures, acceptance criteria, process validation, stability strategy, and proposed reporting category.

Once approved, successful execution may improve predictability and, in some cases, support a reduced reporting category. It is not the same as the comparability exercise itself: the exercise generates and evaluates the evidence; the protocol secures advance agreement on how a future change will be studied and reported.

EU: Linking Comparability to the Variations Framework

The scientific evidence can follow ICH Q5E, but the filing type follows the EU variations framework. Common filing routes include Type IA and Type IB minor variations, Type II major variations, and marketing authorisation extensions. The revised European Commission Variations Guidelines have applied since January 15, 2026.

A complete comparability study does not allow a marketing authorization holder to select a lower variation type at will. Scientific risk, legal classification, procedural requirements, and current regional guidance must be evaluated together.

ICH Q12: Making Future Change More Predictable

ICH Q5E asks whether the product remains comparable. ICH Q12 asks how post-approval CMC changes can be managed more efficiently and predictably throughout the commercial lifecycle.

Tools include Established Conditions, Post-Approval Change Management Protocols (PACMPs), Product Lifecycle Management documents, and the Pharmaceutical Quality System. A PACMP, like an FDA comparability protocol, can establish advance agreement on studies, acceptance criteria, and reporting. Regional implementation still depends on local law and administrative systems.

Where Does Comparability Belong in CTD Module 3?

There is no single universal CTD section. Content may appear in 3.2.S.2, 3.2.S.3, 3.2.S.4, 3.2.S.7, 3.2.P.2, 3.2.P.3, 3.2.P.5, 3.2.P.8, 3.2.A.1, 3.2.A.2, and regional administrative or variation sections.

A strong dossier lets the reviewer follow a clear evidence chain:

Change description → Risk assessment → Study design → Results → Observed differences → Clinical relevance → Comparability conclusion → Updated control strategy

Monoclonal Antibody Site Transfer: A Complete Example

A site-transfer and scale-up comparability strategy connects the manufacturing change, CQA risk, batch strategy, analytical package, process evidence, and stability.

Consider a company transferring a monoclonal antibody drug-substance process from Site A to Site B while scaling the bioreactor from 500 L to 2,000 L.

Change Description

• The cell line and cell bank remain unchanged.

• Upstream scale, bioreactor geometry, and mixing system change.

• The principles of downstream unit operations remain unchanged, but column dimensions and equipment scale change.

• Raw-material specifications remain broadly unchanged, although selected suppliers and site-management systems change.

Risk Assessment

The change-risk assessment should address:

• Glycosylation and charge variants

• Aggregation and fragmentation

• Potency and Fc-mediated functions

• HCP profile and clearance

• Residual DNA

• Process hold times

• Viral clearance and inactivation

• Process consistency and scale effects

Batch Strategy

• Representative Site A commercial or clinical batches

• Site B batches manufactured with the intended commercial process and scale

• A pivotal clinical lot or suitable reference standard as the clinical anchor

• Interpretable sample age and storage histories

Analytical Package

• Primary structure, intact mass, and peptide mapping

• Glycan profiling

• CEX or icIEF charge-variant analysis

• SEC-MALS, CE-SDS, and particle analysis

• Higher-order structure

• Antigen binding, Fc-receptor binding, and cell-based potency

• HCP ELISA with coverage or orthogonal assessment

• Residual DNA, Protein A, endotoxin, and other process-related impurities

Process and Stability Evidence

• Upstream and downstream CPP and IPC comparisons

• Step yields, impurity clearance, and hold-time evaluation

• Site B PPQ

• Real-time stability

• Accelerated and stress-degradation comparisons

Possible Conclusion

If most attributes are highly similar and a small glycan shift remains within the range supported by clinical experience and functional-assay results, a comparable conclusion may be justified.

If the glycan shift also changes Fc-receptor binding or cell-based activity and its clinical impact cannot be excluded, manufacturing more analytically identical batches may add little. Deeper functional, PK/PD, or clinical bridging may be necessary.

Eight Common Practical Mistakes

1. Designing the strategy only after the change and post-change manufacturing are complete.

2. Applying “three lots versus three lots” without a risk- and method-based justification.

3. Comparing only release specifications.

4. Ignoring sample-age and storage bias.

5. Using validated methods without adequate discriminatory power.

6. Ignoring intermediate, clearance, validation, and stability data.

7. Treating statistical significance—or its absence—as the comparability conclusion.

8. Confusing scientific comparability with the regulatory reporting category.

Team Capabilities for Applying ICH Q5E in Practice

A capable cross-functional team should be able to:

• Translate a change description into a mechanism-based risk assessment.

• Maintain traceability among CQAs, process steps, analytical methods, and clinical relevance.

• Design a batch strategy based on risk, process variability, and method capability.

• Distinguish release, characterization, stability, and process-monitoring methods.

• Establish reference-standard and retain-sample strategies before a change.

• Select statistical approaches and explain their limitations.

• Interpret observed differences beyond simple pass-or-fail decisions.

• Decide when analytical evidence is sufficient and when nonclinical or clinical escalation is needed.

• Translate the comparability conclusion into a coherent CTD narrative and regional submission strategy.

• Integrate process development, analytical development, QC, QA, manufacturing, clinical, and regulatory perspectives.

Practical Comparability Plan Checklist

Before implementation, confirm that the change scope and rationale are clear; mechanisms and affected CQAs are identified; sufficient pre-change retains exist; batches are representative; methods can detect expected differences; orthogonal or new methods are planned when needed; acceptance approaches are predefined; sample-age bias is addressed; stability, process validation, and impurity clearance are included; escalation criteria are clear; regional reporting strategies are confirmed; and any need for agency interaction, a comparability protocol, or PACMP has been assessed.

Conclusion: Comparability Is an Evidence Chain, Not a Batch Table

ICH Q5E is not a fixed test list. It is a way of reasoning scientifically about manufacturing change. The team begins with the mechanism of the change, identifies affected quality attributes, selects methods capable of detecting meaningful differences, and integrates analytical, process, stability, clinical, and prior knowledge into a traceable evidence chain.

A good package does not pretend that the pre-change and post-change products are identical. It presents and explains the differences honestly, then answers the central patient-focused question:

Could these differences alter the safety or efficacy of the product patients receive?

The next article in this series will examine biologics control strategy and how raw materials, process parameters, in-process controls, specifications, stability, and lifecycle management work together as an integrated quality system.

LuTra Studio: Turning Manufacturing Change into an Executable Comparability Strategy

Biologics comparability is rarely a single-function exercise. It connects process development, analytical development, manufacturing, QC, QA, clinical, regulatory affairs, supply chain, and external CDMOs.

LuTra Studio provides biotech strategy, CMC, and cross-functional scientific communication consulting to help teams build change-risk assessments, comparability plans, control strategies, technical narratives, and development priorities. If your team is planning a scale-up, site transfer, CDMO technology transfer, analytical-method change, IND/BLA preparation, or post-approval lifecycle program, contact LuTra Studio to discuss an actionable strategy.

References

1. ICH. Q5E: Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process. Step 4, November 18, 2004. https://database.ich.org/sites/default/files/Q5E%20Guideline.pdf

2. EMA. ICH Q5E: Comparability of Biotechnological/Biological Products. https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-5-e-comparability-biotechnologicalbiological-products-step-5_en.pdf

3. FDA. Comparability Protocols for Postapproval Changes to the Chemistry, Manufacturing, and Controls Information in an NDA, ANDA, or BLA. Final Guidance, October 2022. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/comparability-protocols-postapproval-changes-chemistry-manufacturing-and-controls-information-nda

4. FDA. Chemistry, Manufacturing, and Controls Changes to an Approved Application: Certain Biological Products. Final Guidance, June 2021. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chemistry-manufacturing-and-controls-changes-approved-application-certain-biological-products

5. Electronic Code of Federal Regulations. 21 CFR 601.12—Changes to an Approved Application. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-F/part-601/subpart-C/section-601.12

6. ICH. Q12: Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management. Final Version, November 20, 2019. https://database.ich.org/sites/default/files/Q12_Guideline_Step4_2019_1119.pdf

7. EMA. Guidance on the Application of the Revised Variations Framework. https://www.ema.europa.eu/en/guidance-application-revised-variations-framework

8. ICH. Q9(R1): Quality Risk Management. https://database.ich.org/sites/default/files/ICH_Q9%28R1%29_Guideline_Step4_2022_1219.pdf

9. ICH. Q6B: Specifications—Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. 1999. https://database.ich.org/sites/default/files/Q6B%20Guideline.pdf

10. ICH. Q5C: Quality of Biotechnological Products—Stability Testing of Biotechnological/Biological Products. https://database.ich.org/sites/default/files/Q5C_Guideline.pdf